Safinamide

Also known as: (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide, (S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide, FCE-26743, EMD-1195686, NW-1015, PNU-151774E, CS-484, (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide, N-{4-[(3-Fluorobenzyl)oxy]benzyl}-L-alaninamide, Safinamide base

Safinamide (CAS 133865-89-1) is a compound in the Organic Bases category listed in the Jingsj chemical database. It has the molecular formula C17H19FN2O2 and a molecular weight of 302.343 g/mol. Key properties include a melting point of 208-212°, a boiling point of 476.7±40.0 °C at 760 mmHg, a density of 1.2±0.1 g/cm3 and a flash point of 242.1±27.3 °C. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 133865-89-1
Jingsj CID: J-2381-4
Molecular Formula: C₁₇H₁₉FN₂O₂
Molecular Weight: 302.343 g/mol
Category: Organic Bases
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point	208-212°
Boiling Point	476.7±40.0 °C at 760 mmHg
Density	1.2±0.1 g/cm3
Flash Point	242.1±27.3 °C
Exact Mass	302.143066
PSA	64.35000
LogP	2.37
Vapor Pressure	0.0±1.2 mmHg at 25°C
Refractive Index	1.570

Activity & Biological Data

Additional Information	[1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916. [2]. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010 Sep;11(13):2261-8. [3]. Onofrj M, et al. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. [4]. Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs. 2007 Jul;8(7):570-9. [5]. Dal Bo L, et al. Bioassay of safinamide in biological fluids of humans and various animal species. Arzneimittelforschung. 2006;56(12):814-9. http://www.ncbi.nlm.nih.gov/pubmed/17260668

Additional Information

[1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916. [2]. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010 Sep;11(13):2261-8. [3]. Onofrj M, et al. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. [4]. Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs. 2007 Jul;8(7):570-9. [5]. Dal Bo L, et al. Bioassay of safinamide in biological fluids of humans and various animal species. Arzneimittelforschung. 2006;56(12):814-9. http://www.ncbi.nlm.nih.gov/pubmed/17260668

Frequently Asked Questions

What is the CAS number of Safinamide?

The CAS number of Safinamide is 133865-89-1.

What are the molecular formula and molecular weight of Safinamide?

Safinamide has molecular formula C17H19FN2O2 and molecular weight 302.343 g/mol.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Safinamide (CAS 133865-89-1)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-2381-4 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.